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Abstract 
 
Introduction: Painful diabetic neuropathy (PDN) is a disabling pain condition. Its 
pathomechanism remains unknown, but a sensitization and neuronal hyperexcitabilty have 
been suggested. Only symptomatic pharmacological pain-alleviation treatment is currently 
available.  
Areas covered: The origin of PDN is enigmatic, and the evidence-based therapeutic 
guidelines therefore consist only of antidepressants and antiepileptics as first-line 
recommended drugs. This article relates to a MEDLINE/PubMed systematic search (2005-
2015).  
Expert opinion: The results of the meta-analysis from the aspect of the efficacy of 
amitriptyline, duloxetine, venlafaxine, gabapentin and pregabalin are favorable, but the 
placebo response rate is relativ ly high in patients with neuropathic pain. For personalization 
of the medication of PDN patients, the optimum dosing, the genotyping of the metabolizing 
enzymes and optimum biomarkers are needed. As concerns the future perspectives, specific 
sodium channel subtype inhibitors acting on peripheral nociceptive neurons or modified T-
type voltage-gated calcium channel blockers may be promising targets for pharmaceutical 
innovations. Another attractive strategy for the treatment is based on the effects of 
monoclonal antibodies against nerve growth factor, sodium channel, specific receptor and 
cytokines. Botulinum toxin A, capsaicin patch and spinal cord stimulation therapies are the 
nearest future therapeutic options for the treatment of PDN patients.  
 
 
Keywords: antidepressants, antiepileptics, diabetes, metabolism, painful neuropathy, 
pharmacodynamics, pharmacokinetics, treatment 
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Article highlights 
 The pathomechanism of painful diabetic neuropathy is unknown, and therefore only 
symptomatic non-specific treatment is available. 
 As a tricyclic antidepressant, amitriptyline has multimodal action, and is effective with 
a favorable number needed to treat, but it exerts many unfavorable adverse events 
related to its pharmacological profile. 
 The selective serotonin-norepinephrine reuptake inhibitor duloxetine has been 
subjected to pharmacogenomic studies.  
 Venlafaxine has a strong dose-dependent effect and due to its extended release 
formulation, the treatment-related adverse events are low. 
 Gabapentin as an antiepileptic has no metabolism and no drug-drug interactions with a 
high adherence level.  
 Pregabalin as a gabapentinoid with linear kinetics has been strongly recommended for 
the treatment of painful diabetic neuropathy. 
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1. Introduction 
Neuropathic pain (NP), one of the most devastating pain conditions by definition caused by a 
lesion or disease of the somatosensory system [1]. It has distinct clinical features with a 
heterogeneity of different causes [2, 3]. Neuropathic sensory symptoms characterized by 
spontaneous or evoked pain is described as electric shock-like or burning, and other sensory 
disturbances such as paraesthesia, dysaesthesia, allodynia, hyperpathia or hyperalgesia. The 
symptoms of painful diabetic neuropathy (PDN) occur symmetrically in the distal parts of the 
extremities in an ascending manner [4, 5]. The aetiology of NP involves a wide range of 
peripheral or central nervous system (CNS) disorders, including diabetic and other metabolic 
neuropathies, dysimmune neuropathies, postherpetic neuralgia, trigeminal neuralgia, human 
immundeficiency virus (HIV)-associated neuropathy or pain after spinal cord injury, post-
stroke pain, multiple sclerosis-associated pain or cancer-related pain [5].  
Diabetes mellitus is a modern global medical challenge with an estimated prevalence of 366 
million patients in 2030 [6]. Recent epidemiological data showed that the estimated presence 
of NP was around 7% of the general population in Europe [7]. Diabetic neuropathy ocurs in 
59-66% of insulin-dependent (type 1) and non-insulin-dependent (type 2) diabetic patients [8]. 
The adjusted incidence of diabetic polyneuropathy is 54 per 100,000 persons per year [9]. 
Several studies have reported a prevalence of PDN of 10.9-20.0% [10]. Diabetic neuropathy 
and pain occur more frequently in type 2 diabetes mellitus, in women and in non-Caucasians 
[6]
.  
The personal and socio-economic impact of PDN is high, influencing the quality of life, the 
work productivity and the functional disability of the patients [11]. The total annual direct 
medical costs for PDN were recently estimated as 27,931 USD and for severe PDN as 30,755 
USD [11]. PDN has a significant impact on the health-related quality of life [12].  
The pathomechanism of NP has not yet been completely clarified, but the sensitization 
process is widely accepted as playing an important role. Hyperexcitability and sensitization in 
NP similar to migraine as a primary headache disorder involve changes in the peripheral 
nervous system and CNS [5, 13-16]. One of the key elements of the peripheral sensitization is the 
increased expression of voltage-gated sodium channels Nav1.8 and Nav1.9 on lesioned 
peripheral nerves, which are the sources of ectopic pain impulse generation. The upregulation 
of sodium ion channels is a consequence of nerve growth factor (NGF) release from the 
damaged peripheral sensory nerve fibres [17]. NGF is the first discovered member of the 
neurotrophin family. Other members of this family include brain-derived neurotrophic 
factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) [18]. The receptors 
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of these molecules belong to the tropomysin receptor kinase (Trk) family. NGF binds to 
TrkA with high affinity, whereas BDNF and NT-4 bind to TrkB, and NT-3 binds to 
TrkC [19]. These molecules have a common Trk downstream pathway involved in the 
induction of neuropathic pain [19]. Recent clinical findings have shown that anti-NGF 
antibody and small molecule TrkA inhibitors alleviate neuropathic pain [18, 19]. 
Ectopic primary afferent firing clinically explains the devastating spontaneous burning pain 
and unpleasant electric shock-like sensations [20]. Another important mechanism of the 
peripheral sensitization is the presence of the proinflammatory cytokines, bradykinin, 
prostaglandins, 5-hydroxytryptamine and histamine (’inflammatory soup’) along the 
damaged peripheral nerve elements from the dorsal root ganglion (DRG) to the nociceptors in 
the target tissue [17, 20-23]. Human genetic studies revealed the important role of Nav1.7 in 
pain sensation [24]. Nav1.7 is expressed in small-sized nociceptive DRG neurons [25] and 
takes part in spinal cord nociceptive synaptic transmission involved in neuropathic pain 
processing [26, 27]. The importance of Nav1.7 is also highlighted by the findings that its 
expression level was found increased in DRG neurons in diabetic rats [28, 29]. 
Recent findings demonstrate the importance of the microglia function in the central 
sensitization process. The central terminals of the damaged primary sensory neurons in the 
spinal cord release adenosine triphosphate (ATP), which is able to activate the microglia via 
purinergic (P2X4) receptors. The activated microglia releases the BDNF, which activates the 
TrkB receptors, resulting in the down-regulation of the K+ - Cl- cotransporter 2 of the 
nociceptive second-order neurons in spinal lamina I. These nerve cells convey the information 
to the thalamus (the third-order neurons) and project to the somatosensory cortex [21, 30]. 
Excitatory amino acids, mainly glutamate and its receptors (N-methyl-D-aspartate (NMDA) 
receptors), have also been implicated in the pathomechanism of the NP [31]. The membrane 
depolarization caused by nociceptive stimuli permits NMDA receptor-mediated synaptic 
transmission. Calcium influx into the cells activates the non-receptor tyrosine kinase, which 
leads to phosphorylation of the NMDA receptors [31]. This process leads to the glutamate-
related hypersensitivity of the neuronal cells [31] (Figure 1).  
PDN is an underdiagnosed and an undertreated condition in the daily clinical practice [4]. The 
aim of this article is to give an overview of the current evidence-based symptomatic treatment 
of PDN, focusing on the metabolism and toxicological properties of the strongly 
recommended first-line drugs (antidepressants and antiepileptics) in order to promote good 
clinical practice [3, 6, 32]. We also provide data on future therapeutic options (i.e. 
neutrophins, NO-donors, sodium channel blockers, monoclonal antibodies (mAb) 
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against Nav1.7, integrins and NGF, botulinum toxin type A, topical capsaicin patch, 
TRPV1 and TRPA1 antagonists, and neuromodulation approaches), and give an outlook 
toward personalized medicine. The realization of drug-drug and drug-gene interactions 
(i.e. observed or inferred interactions between gene products and drug compounds) are 
fundamental elements of novel pharmaceutical innovation and modern therapeutic 
approaches forPDN patients [33]. 
 
2. Symptomatic pain treatment of PDN 
The exact pathomechanism of the origin of the pain, associated with diabetic neuropathy is 
still lacking, and specific pharmacons for NP do not exist. The currently used drugs for NP 
were originally developed for depression, epilepsy and cancer-related pain, but they are 
effective at different levels in the alleviation of NP. This type of therapy is considered to be 
successful in achieving at least a 50% pain intensity reduction [34]. In this field, it is an 
important fact that the placebo effect for NP is higher than those for other disorders [4].  
Over recent decades, several therapeutic recommendations and guidelines for NP and PDN 
have been put forward [6, 35, 36]. The recent evidence-based recommendations for the oral and 
topical pharmacotherapy of NP were published by the Neuropathic Pain Special Interest 
Group (NeuPSIG) of the International Association for the Study of Pain [3, 7]. The guideline of 
NeuPSIG used the Grading of Recommendation Assessment, Development and Evaluation 
(GRADE) system, which is based on the consensus on the rating of the quality of evidence 
and strength of recommendations ranging from weak to strong for or against the treatment [3, 7, 
37]
.  
This current survey analyses the pharmacological (pharmacokinetic and pharmacodynamic) 
and toxicological properties (absorption, distribution, metabolism and excretion) of the first-
line (strong recommendation) drugs for PDN suggested by the NeuPSIG recommendations.  
 
2.1. Antidepressants 
From the aspect of the efficacious treatment of PDN, among the antidepressive drugs tricyclic 
antidepressants (TCAs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are 
beneficial. Their analgesic effect is independent of their antidepressant properties [7].  
 
2.1.1. Tricyclic antidepressants (TCAs) 
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The group of TCAs involves amitriptyline (AMI), clomipramine, desipramine, imipramine 
and nortryptiline. TCAs generally have similar efficacy as concerns PDN [3]. Particularly AMI 
has been investigated in most clinical trials for PDN [6].  
 
2.1.1.1. Amitriptyline (AMI) 
AMI is a more than 50-year-old drug, which was approved for the indication of depression by 
the US Food and Drug Administration (FDA) in 1961, and is still in use for the treatment of 
PDN world-wide [38].  
The chemical structure of AMI is 3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-ylidene)-
N,N-dimethylpropan-1-amine (Figure 2).  
The mode of action of AMI is the inhibition of the re-uptake of norepinephrine and serotonin 
at the adrenergic nerve endings in the synaptic cleft [39] . It has multimodal actions such as an 
anticholinergic effect, histaminergic down-regulation, gamma-aminobutyric acid (GABA)-B 
receptor up-regulation, α-adrenergic receptor  antagonism and sodium, L-type calcium and 
Kv1.1, Kv7.2, and Kv7.3 voltage-gated potassium ion channel blockade [34, 40, 41]. Importantly, 
AMI is an agonist of the TrkA and TRkB receptors, so it influences the activation of the NGF 
and BDNF [42]. It enhances the neuronal sensitivity to substance P, but does not inhibit the re-
uptake of dopamine or monoamine oxidase [39]. AMI increases the activation of the adenosine 
A1 receptor, which leads to antinociception [40].  
The pharmacokinetic parameters of 75 mg of an orally administered osmotic controlled 
release tablet of AMI revealed that the maximum plasma concentration (Cmax) was 15.3 (+7.0 
standard deviation, S.D.) ng/L, the area under the concentration vs. time curve (AUC) was 
593 (+229 S.D.) ng/mL x h, the time to Cmax (Tmax) was 25.7 (+5.8 S.D.) h and the plasma 
elimination half-life (T1/2) was 20.4 (+4.3 S.D.) h [39]. The bioavailability of AMI is 30-60%, 
the protein binding is 96%. Its active metabolite is nortryptyline [43]. It is metabolized on the 
first pass through the liver by cytochrome P450 (CYP450) isoenzymes (CYP2C19 and 
CYP2D6) and is excreted renally (around 30-50%) (Table 1)[39].  
As regards the pharmacogenetic aspects of AMI, the risk of the lack of efficacy or the 
occurrence of side-effects depends on the types of metabolizer (poor, intermediate, extensive 
or ultrarapid), and the genetic variations of CYP2C19 or CYP2D6 enzymes. The Clinical 
Pharmacogenetics Implementation Consortium recommends therapeutic drug monitoring for 
the guided dose adjustment [44]. 
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The results of clinical trials for managing PDN revealed a superior effect of AMI to placebo 
[45]
. The number needed to treat (NNT) of AMI is 1.3, which means an extremely good rank 
(Table 2) [34].  The recommended daily dose of AMI for PDN is 25-100 mg [4].  
Due to its multimodal actions, AMI resulted in several unfavorable adverse events (AEs) 
regarding anticholinergic, histaminergic, adrenergic, dopamineric and serotoninergic effects 
[43]
. The common (>1% frequency) AEs of AMI are dry mouth, fatigue, somnolence, weight 
gain and dizziness [7, 46]. Contraindications for AMI use are a history of myocardial infarction, 
arrhythmias, heart block, congestive heart failure, coronary artery insufficiency and severe 
liver disease [47]. An increased risk of sudden cardiac death mainly occurs at a dosage of more 
than 100 mg per day [3]. Caution is needed for AMI users with comorbidity, e.g. narrow angle 
glaucoma, urinary retention, prostatic hypertrophy, a history of epilepsy or hyperthyroidism [7, 
47]
.  
The Cochrane Database revealed that AMI was effective for the treatment of PDN, but its 
wide-range use was limited by its unfavorable safety and tolerability profile [48]. The NeuSPIG 
consensus declares that TCAs reached the strong recommendations for use in the treatment of 
PDN [3].  
 
2.1.2. Serotonin-norepinephrine reuptake inhibitors (SNRIs) 
SNRIs have dual effects: they are strong blockers of the reuptake of serotonin and 
norepinephrine. The pharmacological group of SNRIs includes duloxetine (DUL), venlafaxine 
(VEN), desvenlafaxine, milnacipran, levomilnacipran and sibutramine. For the treatment of 
PDN, DUL and VEN have shown good efficacy [34].  
 
2.1.2.1. Duloxetine (DUL) 
DUL was developed in 1988, and FDA approval for depression and PDN was dated in 2004 
[34, 49]
. The chemical structure of DUL is (+)-(S)-N-methyl-3-(naphthalen-1-yloxy)-3-
(thiophen-2-yl) propan-1-amine. It is a potent and selective dual neuronal SNRI 
(serotonin:norepinephrine effects 10:1) [50]. It is a weak inhibitor of dopamine transporters and 
does not have a strong effect on cholinergic, histaminergic, opioid, glutamate and GABA 
reuptake transporters [51-53]. It does not block the monoamine oxidase types A or B [53]. DUL 
has the capability to block the production and/or release of pro-inflammatory cytokines and/or 
can also provoke the production of anti-inflammatory cytokines [54]. DUL has properties for 
the modulation of nitroxidative stress by influencing the balance between pro-oxidant and 
anti-oxidant processes [55]. One of the basic modes of action of DUL in the alleviaton of pain 
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in PDN is based on the blockade of the neuronal sodium ion channel [56]. DUL blocks 
persistent late Nav1.7 Na+ currents preferentially, which may account in part for its analgesic 
action [56]. In a preclinical study it was shown that the impaired norepinephrine homeostasis is 
one of the major factors of the PDN model in rats, and the analgesic effect of DUL might be 
due to the enhancement of noradrenergic signals [57].   
The pharmacokinetic parameters of single oral dose of 60 mg of DUL tablet revealed that 
Cmax was 39-40.1 ng/L, AUC was 584-591 ng x h/mL, Tmax was 6 h and T1/2 was 10.2 h [53, 
58]
. The bioavailability of DUL is 50%, and the protein biding (mainly to albumin) is high 
(>90%), and widely distributed throughout the tissues (the volume of distribution is 
approximately 1640 L) [43, 53, 58]. The steady state of DUL is usually achieved by day 3 of 
administration [53]. Its circulating metabolites are pharmacologically inactive. It is metabolized 
by the liver (CYP1A2 and CYP2D6) and is excreted 70% in the urine and 20% in the faeces 
[43]
.  
The pharmacokinetics of DUL is influenced by the demographic features of the patients, such 
as sex, smoking, age, ethnicity, hepatic and renal function [58]. The genotype of the CYP2D6 
enzyme also influences the pharmacokinetics of DUL [58]. A recent pharmacogenomic study 
concluded that interleukin-6 variants (rs2066992 and rs10242595) may take part in DUL 
response in patients with major depression [59]. In DUL-treated patients with major depressive 
disorder, tests of the single-nucleotide polymorphisms demonstrated that variants in 
corticotropin-releasing hormone receptor 1 were associated with the DUL response [60].  
As concerns the drug-drug interactions of DUL, it should be underlined that activated 
charcoal diminishes DUL exposure and CYP1A2 blockade increases DUL exposure. In the 
presence of fluvoxamine, the AUC of DUL is increased more than 400% and Cmax is 
increased more than 100% [58]. Smoking decreases the DUL plasma concentratin (by 30%) [58]. 
In the presence of DUL with CYP2D6 inhibitors or in CYP2D6 poor metabolizers, the 
exposure of DUL is less increased as compared with CYP1A2 inhibition [58]. DUL has the 
capability to enhance the exposure of pharmacons that are metabolized by CYP2D6, but not 
CYP1A2 [58]. Pharmacodynamic trials suggested that DUL may enhance the effects of 
benzodiazepines, but not alcohol or warfarin [58]. 
The investigation of the AmpliChip CYP450 Genotyping Test for genes CYP2D6 and 
CYP2C19 concluded that poor metabolizers accounted for around 7% of Caucasians for 
CYP2D6 and around 25% of East Asians for CYP2C19, and ultra-rapid metabolizers for 
CYP2D6 of around 29% in North Africa and the Middle-East [61, 62].  
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The recent Cochrane Collaboration meta-analysis pointed out that 60 mg and 120 daily doses 
of DUL were efficacious in the treatment of PDN [63]. The related NNT of benefit of DUL at 
60 mg is 5 (95% confidential interval, CI 4 to 7) in the alleviation of pain in diabetic 
neuropathy [63].  
The recommended daily dose of DUL for PDN is 60-120 mg once a day [3, 4].  
Mild AEs of DUL were frequent at a high dose, such as nausea, dry mouth, headache, 
dizziness and fatigue [7, 53, 63]. The common AEs of DUL (60 mg per day) are somnolence 
(20%) and constipation (14%) [34, 64]. Severe AEs of DUL were rare [63]. Precautions for the 
use of DUL are needed in cases of hepatic disorder, hypertension and concomitant medication 
with tramadol [7].  
The NeuSPIG consensus declared that DUL reached the strong recommendations for use in 
the treatment of PDN [3].  
 
2.1.2.2. Venlafaxine (VEN) 
VEN was launched on the pharmaceutical market after FDA approval in 1993, and VEN 
extended release (XR) in 1997 [50]. Its chemical structure is (RS)-1-[2-dimethylamino-1-(4-
methoxyphenyl)ethyl]cyclohexanol. 
VEN, as parent drug, and its active and structurally-similar major metabolite desvenlafaxine 
(O-desmethylvenlafaxine) are potent and selective dual neuronal SNRIs (VEN: 
serotonin:norepinephrine effects 30:1; desvenlafaxine: 10:1) [50, 65]. VEN has a strong dose-
dependent action: in low doses it inhibits serotonin reuptake, while in higher doses it blocks 
both serotonin and norepinephrine reuptake [66]. VEN and desvenlafaxine modulate the 
dopaminergic neurotransmission at low affinity level [50]. They may not influence the 
adrenergic, muscarinic, cholinergic, histaminergic, benzodiazepine or opioids receptors, or 
monoamine oxidase [65]. There are later data regarding the antinociceptive effect of VEN, 
which revealed that this analgetic effect may be influenced by opioid receptors and the 
alpha2-adrenergic receptor [67]. There are findings which proved that VEN XR can modify 
pituitary adenylate cyclase-activating peptide (PACAP) and its PAC1 receptor genes in 
generalized anxiety disorder [68].  
The pharmacokinetic parameters of orally administered VEN XR tablets of 150 mg revealed 
that Cmax was 150 ug/L, the AUC was 1877 ug/L x h, Tmax was 5.5 h and T1/2 was 5 h [65]. The 
plasma protein binding of VEN XR at 150 mg is 27% and its major metabolic pathway 
proceeds primarily through the liver by enzymes CYP2D6 and CYP3A3/4 [50]. It is mainly 
excreted in the urine (87%) [65] . 
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A recent Cochrane meta-analysis based on six randomized clinical trials showed a positive 
benefit for a daily dose of VEN above 150 mg for the treatment of neuropathic pain (mostly 
PDN) [69]. In the largest multicentre study for PDN, the VEN treatment group (150-225 mg 
daily dose) reached a significantly greater improvement than that for the placebo group at 
week 6 (50% versus 27%) [70]. The NNT of benefit of VEN in the treatment of PDN is 3.1 [34].  
The recommended daily dose of VEN XR for PDN is 150-225 mg once a day [3].  
The most common treatment-emergent AEs of VEN XR were nausea, somnolence and 
hypertension at high dosage [7, 70]. Nausea showed a dose-proportional manner (at 75 mg 22% 
and at 150-225 mg 10%) [71]. Precautions for the use of VEN include cardiac disease, 
hypertension and the administration of tramadol [7].  
The NeuSPIG consensus declared that VEN reached the strong recommendations for use in 
the treatment of PDN [3].  
 
Overall, the above-mentioned antidepressants are all effective in the treatment of PDN. As 
concerns the safety profile of SNRIs, it is a very important fact that the SNRIs have low 
affinity for different neuronal receptors, which results in low AEs. In spite of this, TCAs are 
held to be „dirty drugs” as regards their multireceptorial effects, resulting in high amounts of 
side-effects. In the daily clinical practice, besides the effectiveness and the safety profile of 
the first-line drugs for PDN, the economic aspects are also very important factors. In most 
countries, TCAs are readily available with low charge. DUL is a cost-effective pharmacon for 
the treatment of PDN in the UK [34]. The results of randomized clinical trials and real-world 
studies showed DUL to be more cost-effective than antiepileptics like pregabalin (PREG) in 
PDN therapy [72]. 
 
2.2. Antiepileptics 
Among antiepileptics, only the GABA analogues, gabapentin (GBP), GBP XR and its 
prodrug GBP enacarbil and pregabalin (PREG) have reached the strong recommendation level 
in the treatment of PDN [3, 73]. Each has a similar mechanism of action to inhibit the release of 
presynaptic excitatory neurotransmitters [74]. A wide variety of other antiepileptic drugs were 
inconclusive for recommendation, e.g. carbamazepine, lacosamide, lamotrigine, levetiracetam, 
oxcarbazepine, topiramate, valproate and zonisamide [3, 73]. 
 
 
2.2.1. Gabapentin (GBP) 
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GBP was developed in 1993 and was first marketed in the US in 1994. The FDA later 
approved it for PDN and postherpetic neuralgia [75]. Its chemical structure is 1-
(aminomethyl)cyclohexaneacetic acid.  
The mechanism of analgesic action of GBP in humans has not been clarified, but in animal 
models has been proved that GBP binds to the α2δ subunit of L-type voltage-dependent 
calcium channels [34, 76]. The consequences of this effect are the reduction of the calcium 
currents and inhibition of the presynaptic release of neurotransmitters, such as glutamate and 
substance P [76]. Interestingly, it is structurally related to GABA, but does not bind to GABA-
A or GABA-B receptors, and does not block the uptake or degradation of GABA [76]. The 
main signs of the central sensitization are allodynia and hyperalgesia, which could be 
diminished by GBP [76].  
The pharmacokinetic parameters of orally administered GBP tablets of 600 mg three times 
daily revealed that Cmax was 8.46 mg/L, the AUC was 53.1 mg/L x h, Tmax was 2 h and T1/2 
was 6 h [76]. The plasma protein binding of GBP is less than 3% , it is not significantly 
metabolized, and it is renally excreted in unchanged form [76]. The bioavailability of GBP is 
inversely proportional to the dose: 60% at 900 mg/day and 27% at 4800 mg/day (administered 
in three divided doses) [76]. In contrast, its prodrug, enacarbil, showed essentially linear 
dose-proportional pharmacokinetic properties [77, 78]. GBP has a volume of distribution of 
58 L after 150 mg intravenous administration [76].  
In the available literature, there are no in vitro data on GBP and CYP450 interactions in 
humans, so GBP is neither an inducer nor an inhibitor of the hepatic metabolism of different 
drugs [79]. However, there are data that hydrocodone and morphine can increase GBP 
absorption and the plasma concentration of GBP [80]. Naproxen as a frequently used non-
steroidal antiinflammatory drug (NSAID) can increase Cmax and the AUC of GBP [80]. 
The recent Cochrane Database meta-analysis revealed that the efficacy of GBP for the therapy 
of PDN was superior to placebo (38% versus 21%, NNT 5.9, 95% CI 4.6 to 8.3) [81]. A similar 
effect was seen for standard GBP and a GBP XR formulation [81]. 
The recommended daily dose of GBP for PDN is 1200-3600 mg in three divided doses, while 
that of GBP XR or enacarbil is 1200-3600 mg in two divided doses [3].  
A recent large retrospective clinical study in the United States revealed that among newly 
diagnosed PDN patients the most commonly prescribed drug was GBP (45%) [82]. From the 
aspect of the adherence to treatment during the first year, GBP showed a high adherence level 
versus PREG and DUL [82].  
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The most common AEs of GBP were dizziness (19%), somnolence (14%), peripheral oedema 
(7%), gait disturbance (9%), and also sedation and weight gain [7, 81]. Serious AEs were no 
more frequent as compared with placebo [81]. A precaution concerning the application of GBP 
in a case of renal insufficiency is that a reduced dosage is recommended [7]. 
In a safety issue based on patient withdrawals due to AEs, a meta-analysis revealed that there 
was less withdrawal among patients who take GBP, and the most patient withdrawals due to 
AEs were in the case of AMI [83]. That study concluded in the focus of the benefit-risk 
analysis between six antidepressants and antiepileptics that the best benefit-risk ratio was 
shown by GBP, and the worst one by AMI [83]. 
The NeuSPIG consensus declares that GBP, GBP XR and enacarbil reached the strong 
recommendations for use in the treatment of PDN [3].  
 
2.2.2. Pregabalin (PREG) 
The GABA analogue PREG received the US FDA approval for the treatment of PDN and 
postherpetic neuralgia in 2004 [84]. Its chemical structure is (S)-3-(aminomethyl)-5-
methylhexanoic acid. 
The mode of anti-nociceptive action of PREG is based on the molecular binding to the α2δ 
subunit of the P/Q type of the voltage-gated calcium channel in the CNS, resulting in a 
decreased influx of calcium ion into the neuronal cell [85]. The lack of the required quantity of 
calcium ion in the nerve cells results in the blockade of the propagation of neurotransmission 
due to inadequate synaptic vesicule fusion to the presynaptic membrane of the synapses [85]. 
PREG has a high affinity for α2δ type 1 and 2 proteins versus TCAs (e.g. AMI), SNRIs (e.g. 
VEN) or other antiepileptics (e.g. carbamazepine) [85]. PREG shows strong binding to the pain 
matrix-like cortex or dorsal horn of the spinal cord [85]. The PREG-induced blockade of 
neurotransmitters such as glutamate, glycine, norepinephrine, substance P, calcitonin gene-
related peptide or acetylcholine resulted in inhibition of neuronal excitability and diminished 
the process of the central sensitization in NP [85].  
As a gabapentinoid, PREG does not bind directly to GABA or benzodiazepine or opioid 
receptors. PREG as a glutamic acid decarboxylase (GAD) activator can increase neural 
GABA levels [86].  
The pharmacokinetic parameters of an orally administered single dose of a PREG capsule of 
150 mg revealed that Cmax was 3.99 ng/L, AUC was 28.31 ng/mL x h, Tmax was 1.00 h and 
T1/2 was 5.66 h [87]. The kinetics of PREG showed linear features (proportional to the dosage 
up to 900 mg per day) [88]. The plasma protein binding of PREG is absent and its metabolism 
Page 13 of 35
URL: http://mc.manuscriptcentral.com/eomt  Email: David.Owusu@informa.com
Expert Opinion On Drug Metabolism & Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 14
is negligible, with no effect on the CYP450 system [79, 83, 88]. The bioavailabilty of PREG is 
more than 90% and the volume of distribution 0.5 L/kg [83]. 90% is excreted in the urine as the 
unchanged drug with minor metabolites (e.g. N-methyl-PREG) [83]. It has no interactions 
metabolically with other antiepileptic drugs [79, 80]. 
The results of randomized clinical trials for the use of PREG (300-600 mg per day) in PDN 
revealed significantly better efficacy as compared with placebo [84]. The evidence-based 
guidelines of the American Academy of Neurology announced that PREG is the only drug 
which reached the Level A (top-tier) of evidence in the treatment of PDN [36]. The NNT of 
PREG in the treatment of PDN is 5.0 [34]. 
The recommended daily dose of PREG for PDN is 300-60 mg in two divided doses [3].  
The common major AEs of PREG are sedation, somnolence (less than or around 50%), 
dizziness (less than or around 49%), headache (less than or around 29%), peripheral oedema 
and weight gain [7, 84]. 
There are data for predictive factors for AEs associated with the use of PREG in PDN patients, 
e.g. long duration of therapy – somnolence; advanced age – unsteadiness; elevated serum 
creatinine level – weight gain and oedema [89].  
Precautions for PREG therapy include a reduced dosage in the case of renal failure patients [7].  
The NeuSPIG consensus declares, that PREG reached the strong recommendations for use in 
the treatment of PDN [3].  
 
Taken together, the effectiveness and safety profile of antiepileptics involved in the treatment 
of PDN are based on their pharmacokinetic and pharmacodynamic properties. From their 
licence permission for clinical use their prescription has been increasing, but many PDN 
patients do not receive them or take antiepileptics below the recommended dosage [82, 90].  
 
3. Conclusions 
PDN is a debilitating consequence of diabetes, which greatly affects the quality of life of the 
patient. The exact pathomechanism of PDN is unknown, and causative treatment is therefore 
unavailable. For the symptomatic treatment of PDN, there are first-line strongly 
recommended drugs, such as antidepressants (TCAs: AMI; and SNRIs: DUL and VEN) and 
antiepileptics (only gabapentinoids: GBP and PREG). Among antidepressants, TCAs and 
SNRIs show similar efficacy as concerns PDN, but from the aspect of their AEs, based on 
their pharmacokinetic and pharmacodynamic properties, huge discrepancies may be seen. 
Gabapentinoids have a similar mode of action and effectiveness in the treatment of PDN, but 
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some of their pharmacological properties, such as their bioavailability, absorption and kinetics 
vary, which leads to different features of their therapeutic and safety profiles.   
 
4. Expert opinion 
The treatment of PDN patients is a great challenge for primary care physicians, diabetologists, 
neurologists and even pain specialists. Epidemiological surveys have established that a huge 
number of patients with NP do not receive appropriate treatment [3]. The difficulties in the 
treatment of PDN include the unclear pathomechanism and pathogenesis, and there are no 
specific efficacious pain relief drugs for PDN. It is interesting that the placebo response rate is 
relatively high in NP patients, and especially PDN patients. Focusing on the efficacy of a drug 
used for the alleviation of pain in PDN, we underline the fact, that the placebo effects are 
usually notably strong. This shows the narrow gap between the achieved effectiveness and the 
result of the placebo treatment, which gives a challenge for a novel pharmacological 
innovation for the preparation of new and effective drugs for the successful treatment PDN. 
Unfortunately, the recent evidence-based guidelines consist of only a few first-line strongly 
recommended drugs for the treatment of PDN, such as amitriptyline, duloxetine, venlafaxine, 
gabapentin and pregabalin. All of these have unfavourable AEs and contraindications. The 
correct choice of drugs is a real art of medicine. It is a perpetually recurring question for the 
medical staff to decide which PDN patient should receive which effective, well-tolerated and 
safe drug. Unfortunately, the demographic data or disease characteristics are not predictors for 
the pain alleviation treatment, and they do not help in the choice of the proper medication for 
PDN patients. Another problem is that there are no optimum biomarkers of this field at the 
present. There are some promising data which showed a positive correlation between plasma 
tumor necrosis factor (TNF)alpha levels and macrophages, inducible nitric oxide synthase 
(iNOS) and TNFalpha expression and the severity of the pain in PDN patients [91]. Nitric 
oxide (NO) is an indigenous gas, and its elevated level has been implicated in the 
pathomechanism of PDN [92, 93]. Other potential biomarkers may include certain 
angiogenic and anti-angiogenic factors such as vascular endothelial growth factor, 
soluble endoglin, endothelin-1, and NO, molecules with plasma levels found elevated in 
diabetic patients compared to controls [94]. The furoxan NO donor, PRG150, was 
investigated in the streptozotocin-induced diabetic rat model of PDN and demonstrated 
a dose-dependent analgesic effect, which may represent a novel promising approach in 
PDN [93]. Furthermore, a NO-donating pregabalin, NCX1404, exerted strong 
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antiallodynic response in the streptozocin-induced murine model of PDN. Repeated 
dosing with NCX1404 re-established normal nociceptive response in this model [95]. 
Oxidative stress has a role in the development of microvascular complications in 
patients with diabetic neuropathy. A clinical study revealed a decreased serum prolidase 
enzyme activity, which may be associated with increased NO levels and oxidative stress 
in diabetic patients with neuropathy [96]. In a randomized placebo-controlled study, a 
NO-releasing patch (NitroSense Derma Protect) showed a significant reduction in pain 
of PDN patients [97]. 
We highlight the importance of finding the optimum dose of drugs for PDN, especially in the 
elderly due to the genotyping of the CYP450 enzymes, which play a crucial role in the 
metabolism of these drugs. It is similarly important for better personalizing treatment of PDN 
patients to integrate the CYP genotyping with therapeutic drug monitoring for the safe use of 
medications.   
In the near future it is recommended to guide pharmacogenetic studies based on the genetic 
polymorphisms in different genes (e.g. novel techniques such as AmpliChip CYP450 
Genotyping Test), which can reflect the treatment response to drugs used in PDN.  
At the bedside, one of the major challenges is the interindividual variability to the response to 
the drug used for PDN. As concerns the comorbidities of PDN, the polymedication and the 
genetic polymorphism are other important issues from the aspect of the drug metabolization 
and the drug-drug interactions. For the patients who are ultrarapid metabolizers, the 
pharmacological medications are usually ineffective, while those who are poor metabolizers 
are at high risk of life-threatening toxicity. There is therefore a need for a new aspect of the 
treatment of PDN patients such as determining the genotyping of CYP variant alleles.  
In the coming years, it will be strongly recommended to use the genotyping analysis of 
CYP450 drug-drug and drug-gene interactions in the daily clinical practice in order to 
estimate the effectiveness and safety of the prescribed drugs for PDN. This advanced 
diagnostic method might serve as the basis of the request for personalized medicine.  
The analysis of drug-drug interactions is a crucial part for pharmacokinetic and 
pharmacodynamic studies of the drugs used for PDN. There is a need for methods to evaluate 
pharmacons of this type, e.g. micellar electrokinetic chromatography electrospray ionization-
tandem mass spectrometry, which is a cost-effective technique for measuring VEN and 
desvenlafaxine enantiomers [98].  
One of the potential fields for the causal therapy of PDN is the sodium channel isoforms 
(Nav1.3, Nav1.7, Nav1.8 and Nav1.9) on the peripheral nociceptive neurons. Preclinical and 
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clinical trials have revealed that the blockers of these subtypes of the sodium channels give us 
new fashionable effective drugs against PDN [27].  
The sodium channel voltage sensor monoclonal antibody which targets the peripheral and 
central Nav1.7 channel diminishes itch and neuropathic pain in an animal model [26]. This 
channel-specific antibody may therefore be a potential therapeutic option in human PDN [26, 
99]
.  
Another potential research area may be the modification of the glycosylation of the subclass 
of T-type voltage-gated calcium channels (Cav3.2), which are related to the hyperexcitable 
state of nociceptors in diabetic animal models [100]. In the preclinical state of this research field, 
the classical streptozotocin-induced diabetic rodent model as a reliable way to induce strong 
mechanical allodynia and thermal hyperalgesia is not sufficient to mimic all the aspects of the 
clinical picture of PDN. For future perspectives there is a need for new animal models which 
serve the innovation of the targeted treatment of PDN.  
One of the most promising therapeutic options arises from the technique of fully humanized 
monoclonal antibodies (mAb). There are preclinical data pinpointing the role of integrins, 
receptors for extracellular matrix proteins, in the processes of inflammatory and 
neuropathic hyperalgesia and the chronification of pain [101-103]. The mAbs against the 
beta1 integrin subunit demonstrated an inhibitory effect on prostaglandin E2- and 
epinephrine-induced hyperalgesia in rats [101, 102]. These findings may provide new 
therapeutic options for the treatment of PDN. Antibodies against NGF (e.g. tanezumab, 
fulranumab and fusinumab) in the treatment of osteoarthritis of the hip or knee showed 
superiority in efficacy in pain relief (Western Ontario and McMaster – WOMAC pain) 
and Patient’s Global Assessment compared to placebo [104]. Unfortunately, unexpected 
AEs with tanezumab were reported, such as rapid osteonecrosis with an unknown cause 
at present, a complication necessitating joint replacement surgery [105]. Based on this 
finding, the US Food and Drug Administration placed the studies of all anti-NGF 
monoclonal antibodies on clinical hold [105]. In an early truncated Phase II double-blind 
placebo-controlled trial with fulranumab for the treatment of PDN resulted in a dose-
dependent efficacy, and there was no case necessitating joint replacement therapy [106]. 
Another randomized controlled study with tanezumab forPDN demonstrated pain 
reduction versus placebo; however, there was no significant difference in Patient’s 
Global Assessment scale [107]. 
Another class of mAb against the receptor for advanced glycation and products, which is 
expressed through the sensory nervous system, resulted in a dose-related attenuation of NP in 
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a mouse NP model [108]. Neutralized mAb against interleukin-17A diminished the 
hyperalgesia in a spinal nerve ligation model in mice [109]. Another type of mAb against high-
mobility group box-1 strongly alleviated the mechanical hypersensitivity and the expression 
of matrix metalloproteinase-9 in the partial sciatic nerve ligation model in mice [110]. On the 
basis of the preclinical and early clinical results, we emphasize that mAbs targeting the 
different sites of the pain matrix may give a strong possibility for the causal therapy of PDN.  
Further perspectives emerge from the intradermal application of the botulinum toxin type A 
for PDN. Early clinical studies suggested some effectiveness for benefit for PDN patients [111]. 
Due to these early clinical data, further larger randomized controlled studies are required for 
the evaluation of the efficacy of botulinum toxin type A in this disease.  
The Transient Receptor Potential (TRP) cation channels, including Ankyrin repeat 
domain 1 (TRPA1) and Vanilloid type 1 (TRPV1), have crucial roles in the nociceptive 
process [112, 113]. Recent reports demonstrated that a topical 8% patch of capsaicin, the 
classical TRPV1 agonist, may have a beneficial outcome in PDN patients [114]. The release of 
the final results is waited urgently. In healthy human volunteers, the pharmacokinetic 
profile of TRPV1 antagonists (ABT-102 and JNJ-38893777) were evaluated, and they 
also showed a good tolerability [115, 116]. In a phase 2a (proof-of-concept) study, one of the 
potent and selective TRPA1 antagonist (GRC17536) demonstrated efficacy in patients 
with PDN [117]. Phase 3 studies are warranted in the near future to provide more 
accurate data. At the experimental level, a novel oxime compound, as a potent TRPA1 
and TRPV1 antagonist, has been proven to have promising efficacy on primary sensory 
neurons [113]. This compound might be a new candidate for drug development for the 
treatment of neuropathic pain [113]. 
In the case of pharmacologically refractory PDN, one of the ultimate choices is spinal cord 
stimulation. A multicenter randomized clinical trial concluded that spinal cord stimulation 
significantly alleviated the pain in PDN patients [118]. Neuromodulation methods, such as 
spinal cord stimulation are invasive and expensive techniques, and careful patient selection is 
therefore needed. From the aspect of drug innovation, the targeting of good clinical efficacy, 
tolerability, safety and comparable cost-effectiveness are very important research fields. 
Innovative drug technology is additionally needed to achieve these goals. One example in 
which immediate release versus an XR formulation of VEN were compared, the XR 
formulation showed less AEs (e.g. nausea and dizziness) due to the novel pharmacological 
technology [50].  
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Currently prescribed first-line strongly recommended symptomatic treatment for PDN 
(amitriptyline, duloxetine, venlafaxine, gabapentin, pregabalin) are efficacious, but all have 
limitations due to their precautions and AEs. To attain the better adherence of PDN patients, 
the ultimate goal is a large pharmacogenetic study, with the aim of the drug-drug and drug-
gene interactions. 
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Figures 
 
Figure 1. Scheme of sensitization and hyperexcitability of mechanism of neuropathic 
pain 
 
Modified (Ref.: [5]) 
Abbreviations:  
ATP: adenosine triphosphate, BDNF: brain-derived neurotrophic factor, DRG: dorsal root 
gablgion, Nav1.8 and Nav1.9: voltage-gated sodium channels, NMDA-R: N-methyl-D-
aspartate receptor, NGF: nerve growth factor, P2X4: purinergic receptor, TrkB: tropomysin 
receptor kinase B  
 
Figure 2. Chemical structures of the first-line drugs for painful diabetic neuropathy 
(Ref.: [88, 119-122]) 
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Table legends 
Table 1. Pharmacokinetic and pharmacodynamic properties of the first-line drugs for 
the treatment of PDN 
Abbreviations: AUC: the area under the concentration vs. time curve, Cmax: the maximum 
plasma concentration, h: hours, iv: intravenously, L: litre, NA: not available, PDN: painful 
diabetic neuropathy, Ref.: references, Tmax: the time to Cmax, T1/2: the plasma elimination half-
life, XR: extended release 
 
Table 2. Recommended daily doses and adverse events of the first-line drugs for the 
treatment of PDN 
Abbreviations: NNT: number needed to treat; PDN: painful diabetic neuropathy; XR: 
extended release 
(Ref.: [3, 4, 7, 34, 46, 53, 63, 64, 81, 84] 
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Figure 2. Chemical structures of the first-line drugs for PDN 
 
 
 
Amitriptyline Duloxetine Venlafaxine 
(3-(10,11-Dihydro-5H-
dibenzo[a,d]cycloheptene-5-ylidene)-
N,N-dimethylpropan-1-amine) 
(+)-(S)-N-Methyl-3-(naphthalen-1-yloxy)-
3-(thiophen-2-yl)propan-1-amine 
(RS)-1-[2-dimethylamino-1-(4-
methoxyphenyl)-ethyl]cyclohexanol 
 
 
Gabapentin Pregabalin 
1-(Aminomethyl)cyclohexaneacetic acid (S)-3-(Aminomethyl)-5-methylhexanoic acid 
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Table 1. Pharmacokinetic and pharmacodynamic properties of the first-line drugs for the treatment of PDN 
Drugs Cmax Tmax AUC T1/2 Bioavaila
bility 
Protei
n 
bindin
g 
Volume 
of 
distribut
ion 
Metaboli
sm 
Excretion References 
Antidepressants           
Amitriptyline 
(75 mg tablet) 
15.3 
ng/L 
25.7 
h 
593 
ng/mL x 
h 
20.4 h 30-60% 96% NA CYP2C1
9 
CYP2D6 
urine  
(30-50%) 
faeces 
(NA) 
[39, 43] 
Duloxetine 
(60 mg tablet) 
39-
40.1 
ng/L  
6 h 584-591  
ng x 
h/mL 
10.2 h 50% >90% 1640 L CYP1A2 
CYP2D6 
urine 
(70%) 
faeces 
(20%) 
[50, 53, 58] 
Venlafaxine XR 
(150 mg tablet) 
150.0 
ug/L 
5.5 h 1877 
ug/L x h 
5.0 h NA 27% NA CYP2D6 
CYP3A3
/4 
urine 
(87%) 
faeces 
(NA) 
[65] 
Antiepileptics           
Gabapentin 
(600 mg tablet) 
8.5 
mg/L 
2.0 h 53 mg/L 
x h 
6.0 h 60%  
(900 
mg/day) 
27% 
(4800 
<3% 58 L 
(150 mg 
iv.) 
nil urine 
(NA) 
faeces 
(NA) 
[76, 79, 83] 
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mg/day) 
Pregabalin 
(150 mg capsule) 
4.0 
ng/L 
1 h 28 ug/mL 
x h 
5.7 h 90% absent 0.5 L/kg nil urine 
(90%) 
faeces 
(NA) 
[87, 88] 
Abbreviations: AUC: the area under the concentration vs. time curve, Cmax: the maximum plasma concentration, h: hours, iv: intravenously, L: 
litre, NA: not available, PDN: painful diabetic neuropathy, Ref.: references, Tmax: the time to Cmax, T1/2: the plasma elimination half-life, XR: 
extended release 
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Table 2. Recommended daily doses and adverse events of the first-line drugs for the 
treatment of PDN 
Drugs Recommended  
daily dose (mg) 
NNT Adverse events 
Antidepressants  
Amitriptyline 25-100 mg 1.3 dry mouth, fatigue, somnolence, 
weight gain, dizziness 
Duloxetine 60-120 mg 6.0 nausea, dry mouth, headache, 
dizziness, fatigue, somnolence, 
constipation 
Venlafaxine 
Venlafaxine XR 
150-225 mg 3.1 nausea, somnolence, hypertension 
Antiepileptics  
Gabapentin 
Gabapentin XR 
Gabapentin 
enacarbil 
1200-3600 mg 5.9 dizziness, somnolence, peripheral 
oedema, gait disturbance, sedation, 
weight gain 
Pregabalin 300-600 mg 5.0 sedation, somnolence, dizziness, 
headache, peripheral oedema, weight 
gain 
Abbreviations: NNT: number needed to treat; PDN: painful diabetic neuropathy; XR: 
extended release 
(Ref.: [3, 4, 7, 34, 46, 53, 63, 64, 81, 84]) 
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